Expanded savings programs build on company’s
longstanding commitment to addressing barriers to access and
affordability for patients
AstraZeneca announced it will expand the savings programs for
its entire US inhaled respiratory portfolio, helping eligible
patients pay no more than $35 per month for their medicine.*
Expanding the savings programs will help make its inhalers more
affordable to the most vulnerable patients living with asthma and
chronic obstructive pulmonary disease (COPD), including those who
are uninsured and underinsured.
Pascal Soriot, Chief Executive Officer, AstraZeneca, said:
“AstraZeneca’s expanded savings programs build on our longstanding
commitment to addressing barriers to access and affordability for
patients living with respiratory diseases to ultimately help
patients lead healthier lives. We remain dedicated to addressing
the need for affordability of our medicines, but the system is
complex and we cannot do it alone. It is critical that Congress
bring together key stakeholders to help reform the healthcare
system so patients can afford the medicines they need, not just
today, but for the future.”
Starting June 1, 2024, eligible patients will pay no more than
$35 per month for all AstraZeneca US inhaled respiratory medicines,
including:
- AIRSUPRA® (albuterol and budesonide)
- BEVESPI AEROSPHERE® (glycopyrrolate and formoterol fumarate)
Inhalation Aerosol
- BREZTRI AEROSPHERE® (budesonide, glycopyrrolate, and formoterol
fumarate) Inhalation Aerosol
- SYMBICORT® (budesonide and formoterol fumarate dihydrate)
Inhalation Aerosol
In addition, AstraZeneca substantially reduced the list price of
SYMBICORT on January 1, 2024. The Company will continue to provide
discounts and rebates off the list price to help patients afford
its inhaled respiratory medicines.
For more than 50 years, AstraZeneca has served respiratory
patients by investing in the research and development of new
drug-device combinations, as well as next-generation biologics and
novel mechanisms to address the vast unmet needs of these chronic,
often debilitating diseases. AstraZeneca remains dedicated to
transforming patient outcomes, while ensuring access and
affordability of our innovative medicines.
*Terms and conditions apply. Government restrictions exclude
people enrolled in federal government insurance programs from
co-pay support.
IMPORTANT SAFETY INFORMATION
AIRSUPRA® (albuterol and budesonide)
- Contraindications: Hypersensitivity to albuterol,
budesonide, or to any of the excipients
- Deterioration of Asthma: Asthma may deteriorate acutely
over a period of hours or chronically over several days or longer.
If the patient continues to experience symptoms after using
AIRSUPRA or requires more doses of AIRSUPRA than usual, it may be a
marker of destabilization of asthma and requires evaluation of the
patient and their treatment regimen
- Paradoxical Bronchospasm: AIRSUPRA can produce
paradoxical bronchospasm, which may be life threatening.
Discontinue AIRSUPRA immediately and institute alternative therapy
if paradoxical bronchospasm occurs. It should be recognized that
paradoxical bronchospasm, when associated with inhaled
formulations, frequently occurs with the first use of a new
canister
- Cardiovascular Effects: AIRSUPRA, like other drugs
containing beta2-adrenergic agonists, can produce clinically
significant cardiovascular effects in some patients, as measured by
pulse rate, blood pressure, and/or other symptoms. If such effects
occur, AIRSUPRA may need to be discontinued. In addition,
beta-agonists have been reported to produce electrocardiogram (ECG)
changes, such as flattening of the T wave, prolongation of the QTc
interval, and ST-segment depression. Therefore, AIRSUPRA, like all
sympathomimetic amines, should be used with caution in patients
with cardiovascular disorders, especially coronary insufficiency,
cardiac arrhythmias, and hypertension
- Do Not Exceed Recommended Dose: Clinically significant
cardiovascular effects and fatalities have been reported in
association with excessive use of inhaled sympathomimetic
drugs
- Hypersensitivity Reactions, Including Anaphylaxis: Can
occur after administration of albuterol sulfate and budesonide,
components of AIRSUPRA, as demonstrated by cases of anaphylaxis,
angioedema, bronchospasm, oropharyngeal edema, rash, and urticaria.
Discontinue AIRSUPRA if such reactions occur
- Risk of Sympathomimetic Amines with Certain Coexisting
Conditions: AIRSUPRA, like all therapies containing
sympathomimetic amines, should be used with caution in patients
with convulsive disorders, hyperthyroidism, or diabetes mellitus
and in patients who are unusually responsive to sympathomimetic
amines
- Hypokalemia: Beta-adrenergic agonist medicines may
produce significant hypokalemia in some patients. The decrease in
serum potassium is usually transient, not requiring
supplementation
- Immunosuppression and Risk of Infections: Due to
possible immunosuppression from the use of inhaled corticosteroids
(ICS), potential worsening of infections could occur. Use with
caution. A more serious or fatal course of chickenpox or measles
can occur in susceptible patients
- Oropharyngeal Candidiasis: Has occurred in patients
treated with ICS agents. Monitor patients periodically. Advise
patients to rinse his/her mouth with water, if available, without
swallowing after inhalation
- Hypercorticism and Adrenal Suppression: May occur with
very high doses in susceptible individuals. If such changes occur,
consider appropriate therapy
- Reduction in Bone Mineral Density: Decreases in bone
mineral density have been observed with long-term administration of
ICS. For patients at high risk for decreased bone mineral density,
assess initially and periodically thereafter
- Glaucoma and Cataracts: Have been reported following the
long-term administration of ICS, including budesonide, a component
of AIRSUPRA
- Effects on Growth: Orally inhaled corticosteroids,
including budesonide, may cause a reduction in growth velocity when
administered to pediatric patients. The safety and effectiveness of
AIRSUPRA have not been established in pediatric patients, and
AIRSUPRA is not indicated for use in this population
- Most common adverse reactions (incidence ≥ 1%) are
headache, oral candidiasis, cough, and dysphonia
- Drug Interactions: AIRSUPRA should be administered with
caution to patients being treated with:
- Strong cytochrome P450 3A4 inhibitors (may cause systemic
corticosteroid effects)
- Short-acting bronchodilators (concomitant use of additional
beta-agonists with AIRSUPRA should be used judiciously to prevent
beta-agonist overdose)
- Beta-blockers (may block pulmonary effects of beta-agonists and
produce severe bronchospasm)
- Diuretics or non-potassium-sparing diuretics (may potentiate
hypokalemia or ECG changes). Consider monitoring potassium
levels
- Digoxin (may decrease serum digoxin levels). Consider
monitoring digoxin levels
- Monoamine oxidase inhibitors (MAOI) or tricyclic
antidepressants (Use AIRSUPRA with extreme caution; may potentiate
effect of albuterol on the cardiovascular system)
- Use AIRSUPRA with caution in patients with hepatic impairment,
as budesonide systemic exposure may increase. Monitor patients with
hepatic disease
Please see full Prescribing Information,
including Patient Information.
You may report side effects related to AstraZeneca products.
BEVESPI AEROSPHERE® (glycopyrrolate and formoterol fumarate)
Inhalation Aerosol
CONTRAINDICATIONS
All long-acting beta2-adrenergic agonists (LABAs), including
formoterol fumarate, are contraindicated in patients with asthma
without use of an inhaled corticosteroid. BEVESPI is not indicated
for the treatment of asthma. BEVESPI is contraindicated in patients
with hypersensitivity to glycopyrrolate, formoterol fumarate, or to
any component of the product.
WARNINGS AND PRECAUTIONS
- The safety and efficacy of BEVESPI AEROSPHERE in patients with
asthma have not been established. BEVESPI AEROSPHERE is not
indicated for the treatment of asthma
- Use of LABAs as monotherapy (without inhaled corticosteroids
[ICS]) for asthma is associated with an increased risk of
asthma-related death. These findings are considered a class effect
of LABA monotherapy. When LABAs are used in fixed-dose combination
with ICS, data from large clinical trials do not show a significant
increase in the risk of serious asthma-related events
(hospitalizations, intubations, death) compared to ICS alone.
Available data do not suggest an increased risk of death with use
of LABAs in patients with chronic obstructive pulmonary disease
(COPD)
- BEVESPI should not be initiated in patients with acutely
deteriorating COPD, which may be a life-threatening condition
- BEVESPI should not be used for the relief of acute symptoms
(ie, as rescue therapy for the treatment of acute episodes of
bronchospasm). Acute symptoms should be treated with an inhaled
short-acting beta2-agonist (SABA)
- BEVESPI should not be used more often or at higher doses than
recommended, or with other LABAs, as an overdose may result
- If paradoxical bronchospasm occurs, discontinue BEVESPI
immediately and institute alternative therapy
- If immediate hypersensitivity reactions occur, in particular,
angioedema, urticaria, or skin rash, discontinue BEVESPI at once
and consider alternative treatment
- BEVESPI can produce a clinically significant cardiovascular
effect in some patients, as measured by increases in pulse rate,
blood pressure, or symptoms. If such effects occur, BEVESPI may
need to be discontinued
- Use with caution in patients with convulsive disorders,
thyrotoxicosis, diabetes mellitus, ketoacidosis, and in patients
who are unusually responsive to sympathomimetic amines
- Be alert to hypokalemia and hyperglycemia
- Worsening of narrow-angle glaucoma or urinary retention may
occur. Use with caution in patients with narrow-angle glaucoma,
prostatic hyperplasia, or bladder-neck obstruction, and instruct
patients to contact a physician immediately if symptoms occur
ADVERSE REACTIONS
The most common adverse reactions with BEVESPI (≥2% and more
common than placebo) were cough, 4.0% (2.7%) and urinary tract
infection, 2.6% (2.3%).
DRUG INTERACTIONS
- Use caution if administering additional adrenergic drugs
because the sympathetic effects of formoterol may be
potentiated
- Concomitant treatment with xanthine derivatives, steroids, or
diuretics may potentiate any hypokalemic effect of formoterol
- Use with caution in patients taking non-potassium-sparing
diuretics, as the ECG changes and/or hypokalemia may worsen with
concomitant beta2-agonists
- The action of adrenergic agonists on the cardiovascular system
may be potentiated by monoamine oxidase inhibitors, tricyclic
antidepressants, or other drugs known to prolong the QTc interval.
Therefore, BEVESPI should be used with extreme caution in patients
being treated with these agents
- Use beta-blockers with caution as they not only block the
therapeutic effects of beta-agonists, but may produce severe
bronchospasm in patients with COPD
- Avoid co-administration of BEVESPI with other
anticholinergic-containing drugs as this may lead to an increase in
anticholinergic adverse effects
INDICATION
BEVESPI AEROSPHERE is a combination of glycopyrrolate, an
anticholinergic, and formoterol fumarate, a long-acting
beta2-adrenergic agonist (LABA), indicated for the maintenance
treatment of patients with chronic obstructive pulmonary disease
(COPD), including chronic bronchitis and/or emphysema.
LIMITATION OF USE
Not indicated for the relief of acute bronchospasm or for the
treatment of asthma.
Please read full Prescribing Information,
including Patient Information.
You may report side effects related to AstraZeneca products.
BREZTRI AEROSPHERE® (budesonide, glycopyrrolate, and
formoterol fumarate) Inhalation Aerosol
- BREZTRI is contraindicated in patients who have a
hypersensitivity to budesonide, glycopyrrolate, formoterol
fumarate, or product excipients
- BREZTRI is not indicated for treatment of asthma. Long-acting
beta2-adrenergic agonist (LABA) monotherapy for asthma is
associated with an increased risk of asthma-related death. These
findings are considered a class effect of LABA monotherapy. When a
LABA is used in fixed-dose combination with ICS, data from large
clinical trials do not show a significant increase in the risk of
serious asthma-related events (hospitalizations, intubations,
death) compared with ICS alone. Available data do not suggest an
increased risk of death with use of LABA in patients with COPD
- BREZTRI should not be initiated in patients with acutely
deteriorating COPD, which may be a life-threatening condition
- BREZTRI is NOT a rescue inhaler. Do NOT use to relieve acute
symptoms; treat with an inhaled short-acting beta2-agonist
- BREZTRI should not be used more often than recommended; at
higher doses than recommended; or in combination with
LABA-containing medicines, due to risk of overdose. Clinically
significant cardiovascular effects and fatalities have been
reported in association with excessive use of inhaled
sympathomimetic drugs
- Oropharyngeal candidiasis has occurred in patients treated with
orally inhaled drug products containing budesonide. Advise patients
to rinse their mouths with water without swallowing after
inhalation
- Lower respiratory tract infections, including pneumonia, have
been reported following ICS. Physicians should remain vigilant for
the possible development of pneumonia in patients with COPD as the
clinical features of pneumonia and exacerbations frequently
overlap
- Due to possible immunosuppression, potential worsening of
infections could occur. Use with caution. A more serious or fatal
course of chickenpox or measles can occur in susceptible
patients
- Particular care is needed for patients transferred from
systemic corticosteroids to ICS because deaths due to adrenal
insufficiency have occurred in patients during and after transfer.
Taper patients slowly from systemic corticosteroids if transferring
to BREZTRI
- Hypercorticism and adrenal suppression may occur with regular
or very high dosage in susceptible individuals. If such changes
occur, consider appropriate therapy
- Caution should be exercised when considering the
coadministration of BREZTRI with long-term ketoconazole and other
known strong CYP3A4 Inhibitors. Adverse effects related to
increased systemic exposure to budesonide may occur
- If paradoxical bronchospasm occurs, discontinue BREZTRI
immediately and institute alternative therapy
- Anaphylaxis and other hypersensitivity reactions (eg,
angioedema, urticaria or rash) have been reported. Discontinue and
consider alternative therapy
- Use caution in patients with cardiovascular disorders,
especially coronary insufficiency, as formoterol fumarate can
produce a clinically significant cardiovascular effect in some
patients as measured by increases in pulse rate, systolic or
diastolic blood pressure, and also cardiac arrhythmias, such as
supraventricular tachycardia and extrasystoles
- Decreases in bone mineral density have been observed with
long-term administration of ICS. Assess initially and periodically
thereafter in patients at high risk for decreased bone mineral
content
- Glaucoma and cataracts may occur with long-term use of ICS.
Worsening of narrow-angle glaucoma may occur, so use with caution.
Consider referral to an ophthalmologist in patients who develop
ocular symptoms or use BREZTRI long term. Instruct patients to
contact a healthcare provider immediately if symptoms occur
- Worsening of urinary retention may occur. Use with caution in
patients with prostatic hyperplasia or bladder-neck obstruction.
Instruct patients to contact a healthcare provider immediately if
symptoms occur
- Use caution in patients with convulsive disorders,
thyrotoxicosis, diabetes mellitus, and ketoacidosis or unusually
responsive to sympathomimetic amines
- Be alert to hypokalemia or hyperglycemia
- Most common adverse reactions in a 52-week trial (incidence ≥
2%) were upper respiratory tract infection (5.7%), pneumonia
(4.6%), back pain (3.1%), oral candidiasis (3.0%), influenza
(2.9%), muscle spasms (2.8%), urinary tract infection (2.7%), cough
(2.7%), sinusitis (2.6%), and diarrhea (2.1%). In a 24-week trial,
adverse reactions (incidence ≥ 2%) were dysphonia (3.3%) and muscle
spasms (3.3%)
- BREZTRI should be administered with extreme caution to patients
being treated with monoamine oxidase inhibitors and tricyclic
antidepressants, as these may potentiate the effect of formoterol
fumarate on the cardiovascular system
- BREZTRI should be administered with caution to patients being
treated with:
- Strong cytochrome P450 3A4 inhibitors (may cause systemic
corticosteroid effects)
- Adrenergic drugs (may potentiate effects of formoterol
fumarate)
- Xanthine derivatives, steroids, or non-potassium sparing
diuretics (may potentiate hypokalemia and/or ECG changes)
- Beta-blockers (may block bronchodilatory effects of
beta-agonists and produce severe bronchospasm)
- Anticholinergic-containing drugs (may interact additively).
Avoid use with BREZTRI
- Use BREZTRI with caution in patients with hepatic impairment,
as budesonide and formoterol fumarate systemic exposure may
increase. Patients with severe hepatic disease should be closely
monitored
INDICATION
BREZTRI AEROSPHERE is indicated for the maintenance treatment of
patients with chronic obstructive pulmonary disease (COPD).
LIMITATIONS OF USE
Not indicated for the relief of acute bronchospasm or for the
treatment of asthma.
Please see full BREZTRI Prescribing
Information, including
Patient Information.
You may report side effects related to AstraZeneca products.
SYMBICORT® (budesonide and formoterol fumarate dihydrate)
Inhalation Aerosol
- Use of long-acting beta2-adrenergic agonists (LABA) as
monotherapy (without inhaled corticosteroids [ICS]) for asthma is
associated with an increased risk of asthma-related death.
Available data from controlled clinical trials also suggest that
use of LABA as monotherapy increases the risk of asthma-related
hospitalization in pediatric and adolescent patients. These
findings are considered a class effect of LABA. When LABA are used
in fixed dose combination with ICS, data from large clinical trials
do not show a significant increase in the risk of serious
asthma-related events (hospitalizations, intubations, death)
compared to ICS alone
- SYMBICORT is NOT a rescue medication and does NOT replace
fast-acting inhalers to treat acute symptoms
- SYMBICORT should not be initiated in patients during rapidly
deteriorating episodes of asthma or COPD
- Patients who are receiving SYMBICORT should not use additional
formoterol or other LABA for any reason
- Localized infections of the mouth and pharynx with Candida
albicans has occurred in patients treated with SYMBICORT.
Patients should rinse the mouth after inhalation of SYMBICORT
- Lower respiratory tract infections, including pneumonia, have
been reported following the administration of ICS
- Due to possible immunosuppression, potential worsening of
infections could occur. A more serious or even fatal course of
chickenpox or measles can occur in susceptible patients
- It is possible that systemic corticosteroid effects such as
hypercorticism and adrenal suppression may occur, particularly at
higher doses. Particular care is needed for patients who are
transferred from systemically active corticosteroids to ICS. Deaths
due to adrenal insufficiency have occurred in asthmatic patients
during and after transfer from systemic corticosteroids to less
systemically available ICS
- Caution should be exercised when considering administration of
SYMBICORT in patients on long-term ketoconazole and other known
potent CYP3A4 inhibitors
- As with other inhaled medications, paradoxical bronchospasm may
occur with SYMBICORT
- Immediate hypersensitivity reactions may occur, as demonstrated
by cases of urticaria, angioedema, rash, and bronchospasm
- Excessive beta-adrenergic stimulation has been associated with
central nervous system and cardiovascular effects. SYMBICORT should
be used with caution in patients with cardiovascular disorders,
especially coronary insufficiency, cardiac arrhythmias, and
hypertension
- Long-term use of ICS may result in a decrease in bone mineral
density (BMD). Since patients with COPD often have multiple risk
factors for reduced BMD, assessment of BMD is recommended prior to
initiating SYMBICORT and periodically thereafter
- ICS may result in a reduction in growth velocity when
administered to pediatric patients
- Glaucoma, increased intraocular pressure, and cataracts have
been reported following the administration of ICS, including
budesonide, a component of SYMBICORT. Close monitoring is warranted
in patients with a change in vision or history of increased
intraocular pressure, glaucoma, or cataracts
- In rare cases, patients on ICS may present with systemic
eosinophilic conditions
- SYMBICORT should be used with caution in patients with
convulsive disorders, thyrotoxicosis, diabetes mellitus,
ketoacidosis, and in patients who are unusually responsive to
sympathomimetic amines
- Beta-adrenergic agonist medications may produce hypokalemia and
hyperglycemia in some patients
- The most common adverse reactions ≥3% reported in asthma
clinical trials included nasopharyngitis, headache, upper
respiratory tract infection, pharyngolaryngeal pain, sinusitis,
pharyngitis, rhinitis, influenza, back pain, nasal congestion,
stomach discomfort, vomiting, and oral candidiasis
- The most common adverse reactions ≥3% reported in COPD clinical
trials included nasopharyngitis, oral candidiasis, bronchitis,
sinusitis, and upper respiratory tract infection
- SYMBICORT should be administered with caution to patients being
treated with MAO inhibitors or tricyclic antidepressants, or within
2 weeks of discontinuation of such agents
- Beta-blockers may not only block the pulmonary effect of
beta-agonists, such as formoterol, but may produce severe
bronchospasm in patients with asthma
- ECG changes and/or hypokalemia associated with
nonpotassium-sparing diuretics may worsen with concomitant
beta-agonists. Use caution with the coadministration of
SYMBICORT
INDICATIONS
- SYMBICORT is indicated for the treatment of asthma in patients
6 years and older not adequately controlled on a long-term
asthma-control medication such as an ICS or whose disease warrants
initiation of treatment with both an ICS and LABA (also see DOSAGE
AND ADMINISTRATION).
- SYMBICORT 160/4.5 is indicated for the maintenance treatment of
airflow obstruction in patients with chronic obstructive pulmonary
disease (COPD), including chronic bronchitis and/or emphysema, and
to reduce COPD exacerbations.
- SYMBICORT is NOT indicated for the relief of acute
bronchospasm.
Please see full Prescribing Information, including
Patient Information.
You may report side effects related to AstraZeneca products.
Notes
About Asthma
Asthma is a chronic, inflammatory respiratory disease with
variable symptoms that affects as many as 262 million people
worldwide,1 including approximately 25 million in the US.2
Patients with asthma experience recurrent breathlessness and
wheezing, which varies over time, and in severity and frequency.3
These patients are at risk of severe exacerbations regardless of
their disease severity, adherence to treatment or level of
control.4-5
There are an estimated 136 million asthma exacerbations globally
per year,6 including approximately 10 million in the US2; these are
physically threatening and emotionally significant for many
patients7 and can be fatal.3,8
Inflammation is central to both asthma symptoms4 and
exacerbations.9 Many patients experiencing asthma symptoms use a
SABA (e.g., albuterol) as a rescue medicine10-12; however, taking a
SABA alone does not address inflammation, leaving patients at risk
of severe exacerbations,13 which can result in impaired quality of
life,14 hospitalization15 and frequent oral corticosteroid (OCS)
use.15 Treatment of exacerbations with as few as 1-3 short courses
of OCS are associated with an increased risk of adverse health
conditions including type 2 diabetes, depression/anxiety, renal
impairment, cataracts, cardiovascular disease, pneumonia and
fracture.16 International recommendations from the GINA no longer
recommend SABA alone as the preferred rescue therapy.3
About COPD
COPD refers to a group of lung diseases, including chronic
bronchitis and emphysema, that cause airflow blockage and
breathing-related problems.17 Affecting an estimated 16 million
Americans, COPD is the third leading cause of death due to chronic
disease and the sixth overall leading cause of death in the
US.18-19
About AIRSUPRA®
AIRSUPRA (albuterol and budesonide), formerly known as PT027, is
a first-in-class SABA/ICS rescue treatment for asthma in the US, to
be taken as needed. It is an inhaled, fixed-dose combination rescue
medication containing albuterol (also known as salbutamol), a SABA,
and budesonide, a corticosteroid, and has been developed in a pMDI
using AstraZeneca’s Aerosphere delivery technology.
The FDA approval of AIRSUPRA was based on MANDALA and DENALI
Phase III trials (Approval press release). In MANDALA, AIRSUPRA
significantly reduced the risk of severe exacerbations compared to
albuterol in patients with moderate-to-severe asthma when used as
an as-needed rescue medication in response to symptoms. For
patients treated with AIRSUPRA 180 mcg/160 mcg the annualized total
systemic corticosteroids dose when compared with albuterol 180 mcg
was statistically significantly different, with a reduction in mean
annualized dose of 40 mg per patient. In DENALI, AIRSUPRA
significantly improved lung function compared to the individual
components albuterol and budesonide in patients with mild to
moderate asthma.
About BEVESPI AEROSPHERE®
BEVESPI AEROSPHERE (glycopyrronium and formoterol fumarate) is a
fixed-dose dual bronchodilator in a pMDI, combining glycopyrronium,
a long-acting muscarinic antagonist (LAMA), and formoterol
fumarate, a long-acting beta2-agonist (LABA). PMDIs are an
important choice for COPD patients where limited lung function,
advanced age and reduced dexterity or cognition are significant
considerations for patients to achieve therapeutic benefits from
their medicines. BEVESPI AEROSPHERE is the only LABA/LAMA with
Aerosphere delivery technology. Results from an imaging trial have
shown that BEVESPI AEROSPHERE effectively delivers medicine to both
the large and small airways.
About BREZTRI AEROSPHERE®
BREZTRI AEROSPHERE (budesonide, glycopyrrolate, and formoterol
fumarate) is a single-inhaler, fixed-dose triple-combination of
formoterol fumarate, a LABA, glycopyrronium bromide, a LAMA, with
budesonide, an ICS, and delivered in a pressurized metered-dose
inhaler. BREZTRI AEROSPHERE is approved to treat COPD in more than
50 countries worldwide including the US, EU, China and Japan, and
is currently being studied in Phase III trials for asthma.
About SYMBICORT®
Symbicort (budesonide and formoterol fumarate dihydrate) is the
number one ICS/LABA combination therapy in asthma and chronic
obstructive pulmonary disease (COPD) in China. It is a combination
formulation containing budesonide, an ICS that treats underlying
inflammation, and formoterol, a LABA with a fast onset of action,
in a single inhaler. Symbicort was launched in 2000 and is approved
in approximately 120 countries to treat asthma and/or COPD either
as Symbicort Turbuhaler or Symbicort pMDI (pressurised metered-dose
inhaler).
About AstraZeneca in Respiratory & Immunology
Respiratory & Immunology, part of BioPharmaceuticals, is one
of AstraZeneca’s main disease areas and is a key growth driver for
the Company.
AstraZeneca is an established leader in respiratory care with a
50-year heritage. The Company aims to transform the treatment of
asthma and COPD by focusing on earlier biology-led treatment,
eliminating preventable asthma attacks, and removing COPD as a
top-three leading cause of death. The Company’s early respiratory
research is focused on emerging science involving immune
mechanisms, lung damage and abnormal cell-repair processes in
disease and neuronal dysfunction.
With common pathways and underlying disease drivers across
respiratory and immunology, AstraZeneca is following the science
from chronic lung diseases to immunology-driven disease areas. The
Company’s growing presence in immunology is focused on five mid- to
late-stage franchises with multi-disease potential, in areas
including rheumatology (including systemic lupus erythematosus),
dermatology, gastroenterology, and systemic eosinophilic-driven
diseases. AstraZeneca’s ambition in Respiratory & Immunology is
to achieve disease modification and durable remission for millions
of patients worldwide.
AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company
that focuses on the discovery, development, and commercialization
of prescription medicines in Oncology, Rare Diseases, and
BioPharmaceuticals, including Cardiovascular, Renal &
Metabolism, and Respiratory & Immunology. Based in Cambridge,
UK, AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. Please visit
www.astrazeneca-us.com and follow us on social media
@AstraZeneca.
About AZ&Me™
AstraZeneca’s patient assistance program, AZ&Me Prescription
Savings Program (AZ&Me), is part of the Company’s commitment to
addressing barriers to access and affordability to improve
medication adherence, enhance patient care, and help patients lead
healthier lives. AZ&Me is just one of the ways that AstraZeneca
makes its life-changing medicines widely available, accessible, and
affordable.
For over 40 years, AstraZeneca has offered a patient assistance
program through AZ&Me and prior legacy free drug programs,
making it one of the longest standing patient assistance programs
in the country. Since 2007, over five million people have benefited
from this program. In addition to its patient assistance programs,
AstraZeneca offers other affordability programs and resources to
help increase patients’ access to medicines and reduce their
out-of-pocket costs including a co-pay savings program for
commercially-insured patients and additional affordability
resources. Each of these programs offer financial support to
particular patient populations, consistent with applicable legal
requirements.
The goal of AZ&Me is to help patients who have been
prescribed an AstraZeneca medication and are having difficulty
affording it. Patients enrolled in AZ&Me receive their
AstraZeneca medicine for free. To learn more, visit
AZ&Me.com.
References
- The Global Asthma Report 2022. Accessed: March 2024.
http://globalasthmareport.org/index.html
- Centers for Disease Control and Prevention (CDC). Most Recent
National Asthma Data. Accessed: March 2024.
https://www.cdc.gov/asthma/most_recent_national_asthma_data.htm
- Global Initiative for Asthma. Updated May 2023. Accessed: March
2024. www.ginasthma.org
- Price D, et al. Asthma control and management in 8,000 European
patients: the REcognise Asthma and LInk to Symptoms and Experience
(REALISE) survey. NPJ Prim Care Respir Med. 2014;24:14009.
- Papi A, et al. Relationship of inhaled corticosteroid adherence
to asthma exacerbations in patients with moderate-to-severe asthma.
J Allergy Clin Immunol Pract. 2018;6(6): 1989-1998.e3.
- Data on File. REF-173201. AstraZeneca Pharmaceuticals LP.
- Sastre J, et al. Insights, attitudes, and perceptions about
asthma and its treatment: a multinational survey of patients from
Europe and Canada. World Allergy Organ J. 2016;9:13.
- Fernandes AG, et al. Risk factors for death in patients with
severe asthma. J Bras Pneumol. 2014;40(4):364-372.
- Wark PA, et al. Asthma exacerbations. 3: Pathogenesis. Thorax.
2006;61(10):909-915.
- Johnson DB, et al. Albuterol. In: StatPearls. Treasure Island
(FL): StatPearls Publishing; 2024 Jan 10.
- Montemayor T, et al. Albuterol: Often Used and Heavily Abused.
Respiratory Care. November 2021, 66 (Suppl 10) 3603775.
- ClinCalc.com. Albuterol Drug Usage Statistics, United States,
2013-2020. Accessed: March 2024.
https://clincalc.com/DrugStats/Drugs/Albuterol
- Nwaru BI, et al. Overuse of short-acting β2-agonists in asthma
is associated with increased risk of exacerbation and mortality: a
nationwide cohort study of the global SABINA programme. Eur Respir
J. 2020;55(4):1901872.
- Lloyd A, et al. The impact of asthma exacerbations on
health-related quality of life in moderate to severe asthma
patients in the UK. Prim Care Respir J. 2007;16(1):22-27.
- Bourdin A, et al. ERS/EAACI statement on severe exacerbations
in asthma in adults: facts, priorities and key research questions.
Eur Respir J. 2019;54(3):1900900.
- Price DB, et al. Adverse outcomes from initiation of systemic
corticosteroids for asthma: long-term observational study. J Asthma
Allergy. 2018;11:193-204.
- GOLD. Global Strategy for the Diagnosis, Management and
Prevention of COPD, Global Initiative for Chronic Obstructive Lung
Disease (GOLD) 2024. [Online]. Accessed: March 2024.
https://goldcopd.org/2024-gold-report/
- National Heart, Lung, and Blood Institute. What is COPD?
Accessed: March 2024. https://www.nhlbi.nih.gov/health/copd
- Centers for Disease Control and Prevention. Leading Causes of
Death. Accessed: March 2024.
https://www.cdc.gov/nchs/fastats/leading-causes-of-death.htm
# US-87197 Last Updated 3/24
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240318005558/en/
Brendan McEvoy +1 302 885 2677 Jillian Gonzales +1 302 885
2677
US Media Mailbox: usmediateam@astrazeneca.com
AstraZeneca (NASDAQ:AZN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
AstraZeneca (NASDAQ:AZN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024